vs
NorthEast Community Bancorp, Inc.（NECB）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是NorthEast Community Bancorp, Inc.的1.1倍（$30.3M vs $26.4M），NorthEast Community Bancorp, Inc.净利率更高（40.9% vs -221.3%，领先262.2%），REGENXBIO Inc.同比增速更快（43.0% vs 3.9%），NorthEast Community Bancorp, Inc.自由现金流更多（$50.8M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 1.8%）
东北社区银行（马里兰州）是一家美国银行控股公司，主要在大西洋中部地区运营，面向个人用户和本地企业提供存款业务、抵押贷款、小微企业融资、财富管理等全品类零售及商业金融服务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
NECB vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.1倍
$26.4M
营收增速更快
RGNX
高出39.1%
3.9%
净利率更高
NECB
高出262.2%
-221.3%
自由现金流更多
NECB
多$103.6M
$-52.8M
两年增速更快
RGNX
近两年复合增速
1.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $26.4M | $30.3M |
| 净利润 | $10.8M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 59.0% | -190.0% |
| 净利率 | 40.9% | -221.3% |
| 营收同比 | 3.9% | 43.0% |
| 净利润同比 | 5.8% | -31.2% |
| 每股收益（稀释后） | $0.78 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NECBRGNX
| Q4 25 | $26.4M | $30.3M | ||
| Q3 25 | $27.0M | $29.7M | ||
| Q2 25 | $25.9M | $21.4M | ||
| Q1 25 | $25.5M | $89.0M | ||
| Q4 24 | $25.4M | $21.2M | ||
| Q3 24 | $27.6M | $24.2M | ||
| Q2 24 | $27.0M | $22.3M | ||
| Q1 24 | $25.5M | $15.6M |
净利润NECBRGNX
| Q4 25 | $10.8M | $-67.1M | ||
| Q3 25 | $11.9M | $-61.9M | ||
| Q2 25 | $11.2M | $-70.9M | ||
| Q1 25 | $10.6M | $6.1M | ||
| Q4 24 | $10.2M | $-51.2M | ||
| Q3 24 | $12.7M | $-59.6M | ||
| Q2 24 | $12.8M | $-53.0M | ||
| Q1 24 | $11.4M | $-63.3M |
毛利率NECBRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率NECBRGNX
| Q4 25 | 59.0% | -190.0% | ||
| Q3 25 | 61.6% | -176.3% | ||
| Q2 25 | 59.5% | -296.3% | ||
| Q1 25 | 57.4% | 13.6% | ||
| Q4 24 | 57.0% | -242.1% | ||
| Q3 24 | 63.6% | -256.6% | ||
| Q2 24 | 65.6% | -251.3% | ||
| Q1 24 | 62.7% | -408.8% |
净利率NECBRGNX
| Q4 25 | 40.9% | -221.3% | ||
| Q3 25 | 44.0% | -208.3% | ||
| Q2 25 | 43.1% | -331.8% | ||
| Q1 25 | 41.4% | 6.8% | ||
| Q4 24 | 40.1% | -241.3% | ||
| Q3 24 | 45.9% | -246.3% | ||
| Q2 24 | 47.5% | -237.7% | ||
| Q1 24 | 44.5% | -405.4% |
每股收益（稀释后）NECBRGNX
| Q4 25 | $0.78 | $-1.30 | ||
| Q3 25 | $0.87 | $-1.20 | ||
| Q2 25 | $0.82 | $-1.38 | ||
| Q1 25 | $0.78 | $0.12 | ||
| Q4 24 | $0.74 | $-0.99 | ||
| Q3 24 | $0.95 | $-1.17 | ||
| Q2 24 | $0.97 | $-1.05 | ||
| Q1 24 | $0.86 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $81.2M | $230.1M |
| 总债务越低越好 | $70.0M | — |
| 股东权益账面价值 | $351.7M | $102.7M |
| 总资产 | $2.1B | $453.0M |
| 负债/权益比越低杠杆越低 | 0.20× | — |
8季度趋势，按日历期对齐
现金及短期投资NECBRGNX
| Q4 25 | $81.2M | $230.1M | ||
| Q3 25 | $64.3M | $274.2M | ||
| Q2 25 | $59.4M | $323.3M | ||
| Q1 25 | $89.5M | $267.9M | ||
| Q4 24 | $78.3M | $234.7M | ||
| Q3 24 | $97.8M | $255.5M | ||
| Q2 24 | $113.9M | $290.4M | ||
| Q1 24 | $107.4M | $338.7M |
总债务NECBRGNX
| Q4 25 | $70.0M | — | ||
| Q3 25 | $170.0M | — | ||
| Q2 25 | $135.0M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $7.0M | — | ||
| Q2 24 | $47.0M | — | ||
| Q1 24 | $47.0M | — |
股东权益NECBRGNX
| Q4 25 | $351.7M | $102.7M | ||
| Q3 25 | $344.0M | $161.5M | ||
| Q2 25 | $336.7M | $213.7M | ||
| Q1 25 | $327.2M | $274.2M | ||
| Q4 24 | $318.3M | $259.7M | ||
| Q3 24 | $309.6M | $301.4M | ||
| Q2 24 | $300.0M | $348.3M | ||
| Q1 24 | $288.9M | $390.7M |
总资产NECBRGNX
| Q4 25 | $2.1B | $453.0M | ||
| Q3 25 | $2.1B | $525.2M | ||
| Q2 25 | $2.0B | $581.0M | ||
| Q1 25 | $1.9B | $490.9M | ||
| Q4 24 | $2.0B | $466.0M | ||
| Q3 24 | $2.0B | $519.1M | ||
| Q2 24 | $1.9B | $569.4M | ||
| Q1 24 | $1.9B | $629.2M |
负债/权益比NECBRGNX
| Q4 25 | 0.20× | — | ||
| Q3 25 | 0.49× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.16× | — | ||
| Q1 24 | 0.16× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $52.6M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $50.8M | $-52.8M |
| 自由现金流率自由现金流/营收 | 192.3% | -174.0% |
| 资本支出强度资本支出/营收 | 6.6% | 1.7% |
| 现金转化率经营现金流/净利润 | 4.86× | — |
| 过去12个月自由现金流最近4个季度 | $89.9M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流NECBRGNX
| Q4 25 | $52.6M | $-52.3M | ||
| Q3 25 | $14.1M | $-56.0M | ||
| Q2 25 | $15.6M | $-49.3M | ||
| Q1 25 | $10.9M | $33.6M | ||
| Q4 24 | $48.7M | $-31.6M | ||
| Q3 24 | $14.4M | $-40.5M | ||
| Q2 24 | $11.1M | $-45.5M | ||
| Q1 24 | $12.9M | $-55.5M |
自由现金流NECBRGNX
| Q4 25 | $50.8M | $-52.8M | ||
| Q3 25 | $13.6M | $-56.5M | ||
| Q2 25 | $14.9M | $-49.7M | ||
| Q1 25 | $10.6M | $32.6M | ||
| Q4 24 | $48.2M | $-32.7M | ||
| Q3 24 | $14.2M | $-40.9M | ||
| Q2 24 | $11.0M | $-46.0M | ||
| Q1 24 | $12.8M | $-56.0M |
自由现金流率NECBRGNX
| Q4 25 | 192.3% | -174.0% | ||
| Q3 25 | 50.5% | -189.9% | ||
| Q2 25 | 57.3% | -232.8% | ||
| Q1 25 | 41.4% | 36.6% | ||
| Q4 24 | 189.3% | -154.2% | ||
| Q3 24 | 51.5% | -168.9% | ||
| Q2 24 | 40.8% | -206.2% | ||
| Q1 24 | 50.3% | -358.5% |
资本支出强度NECBRGNX
| Q4 25 | 6.6% | 1.7% | ||
| Q3 25 | 1.6% | 1.7% | ||
| Q2 25 | 2.9% | 1.8% | ||
| Q1 25 | 1.5% | 1.2% | ||
| Q4 24 | 2.0% | 5.1% | ||
| Q3 24 | 0.6% | 1.3% | ||
| Q2 24 | 0.5% | 2.1% | ||
| Q1 24 | 0.3% | 3.6% |
现金转化率NECBRGNX
| Q4 25 | 4.86× | — | ||
| Q3 25 | 1.18× | — | ||
| Q2 25 | 1.40× | — | ||
| Q1 25 | 1.04× | 5.53× | ||
| Q4 24 | 4.77× | — | ||
| Q3 24 | 1.14× | — | ||
| Q2 24 | 0.87× | — | ||
| Q1 24 | 1.13× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NECB
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
